Caso 1 30/m |
EA 10 a |
Não |
Etanercept 2,5 m |
PM |
(-) |
Pulso de MP (1,0 g) |
Melhoria |
ANA1:160 Anti Jo-1 |
Caso 2 20/f |
AR 2 a |
Mtx |
Adalimumabe 6 m |
PM |
(-) |
Pulso de MP (1,0 g) |
Melhoria |
ANA1:320 Anti Jo-1 |
Caso 3 44/f |
AR 7 a |
Mtx |
Adalimumabe 36 m |
DM |
(+) |
Pulso de MP (1,0 g), CY |
Resposta Parcial |
ANA 1:320 Anti Jo-1 |
Musial 200344 Musial J, Undas A, Celinska-Lowenhoff M. Polymyositis associated with infliximab treatment for RA. Rheumatology (Oxford). 2003;42:1566-8.
52/f |
AR 20 a |
Mtx |
Infliximabe 30 m |
PM |
(+) |
Pulso de MP (1,0 g) |
Melhoria |
ANA 1:320 AntidsDNA1:20 Anti Jo-1 |
Flendrie 200355 Flendrie M, Creemers MCW, Welsing PMC, Den Broeder AA, VanRiel PLCM. Survival during treatment with tumour necrosis factor blocking agents in RA. Ann Rheum Dis. 2003;62:30-3.,
|
AR
|
|
|
PM |
|
|
|
|
Flendrie 200566 Flendrie M, Vissers WHPM, Creemers MCW, de Jong J, Van de EMG, Kerkhof KCM, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with RA: a prospective study. Arthritis Res Ther. 2005;7:R666-76.
52/f |
AR
|
|
Lenercept
|
DM |
|
|
Melhoria |
|
Urata 200677 Urata Y, Wakai Y, Kowatari K. Polymyositis associated with infliximab treatment for RA. Mod Rheumatol. 2006;16:410-1.
52/f |
AR 33 a |
Mtx |
Infliximabe 9 m |
PM |
(+) |
30 mg de MP |
Melhoria |
ANA 1:640 Anti Jo-1 |
Hall 200688 Hall HA, Bernard Z. Evolution of dermatomyositis during therapy with a tumor necrosis factor α inhibitor. Arthritis Rheumatol. 2006;55:982-4.
44/f |
AR 1 a |
Mtx HCQ |
Etanercept 6 m |
DM |
(+) |
Altas doses de MP, AZP, MTX |
Melhoria |
ANA1:640 Anti Jo-1 |
Liozon 200799 Liozon E, Ouattara B, Loustaud-Ratti V, Vidal E. Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma. Scand J Rheumatol. 2007;36:484-6.
42/f |
AR 1,5 a |
Mtx HCQ |
Etanercept 9 m |
PM |
(+) |
Altas doses de MP, CY |
Melhoria |
ANA 1:2560 Anti-PM-Scl |
Kiltz 20081010 Kiltz U, Fendler C, Braun J. Neuromuscular involvement in rheumatic patients treated with anti-TNF therapy—three examples. J Rheumatol. 2008;35:2074-5.
57/f |
AR 26 a |
Mtx HCQ |
Etanercept 30 m |
PM |
(+) |
Altas doses de MP, CY |
Melhoria |
ANA 1:2.560 |
Kiltz 20081010 Kiltz U, Fendler C, Braun J. Neuromuscular involvement in rheumatic patients treated with anti-TNF therapy—three examples. J Rheumatol. 2008;35:2074-5.
46/m |
EA 17 a |
|
Infliximabe 6 m |
PM |
(-) |
|
Melhoria |
Não |
Ramos-Casals 20081111 Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF targeted therapies. Best Pract Res. 2008;22:847-61.
4 pacientes |
AR
|
|
Infliximabe (2 p) Etanercept Lenercept |
PM (2 p) DM (2 p) |
|
|
|
|
Brunasso 20101212 Brunasso AG, Lo Scocco G, Massone C. Dermatomyositis during adalimumab therapy for RA. J Rheumatol. 2010;37:1549-50.
45/f |
AR 13 a |
Não |
Adalimumabe 34 m |
DM |
(-) |
MP |
Melhoria |
ANA 1:320 |
Klein 20101313 Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010;146:780-4.
33/f |
AR
|
Não |
Etanercept 5 m |
DM |
(+) |
MP |
Melhoria |
Não |
Klein 20101313 Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010;146:780-4.
40/f |
AR
|
Não |
Etanercept 2 a |
DM |
(-) |
MP |
Resposta parcial |
ANA |
Klein 20101313 Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010;146:780-4.
29/f |
ASN
|
Mtx |
Adalimumabe 3 m |
DM |
(-) |
MP, Mtx, AZP, Quinacrina |
Melhoria |
ANA 1:640 |
Ishiguro, 20101414 Ishiguro T, Takayanagi N, Miyahara Y, Yanagisawa T, Sugita Y. Antisynthetase (anti PL-7 antibody) syndrome presenting as a skin rash and exacerbation of interstitial pneumonia during treatment for RA. Nihon Kokyuki Gakkai Zasshi. 2010;48:240-6.
52/m |
AR 12 a |
Mtx, Buc, Tac |
Etanercept 26 m |
DM |
(+) |
Pulso de MP (1,0 g) |
Melhoria |
Anti-PL-7 |
Ishikawa 201033 Ishikawa Y, Yukawa N, Ohmura K, Hosono Y, Imura Y, Kawabata D, et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with RA: a case report and review of the literature. Clin Rheumatol. 2010;29:563-6.
58/f |
AR 2 a |
Buc, Tac |
Etanercept 2 m |
PM |
(+) |
Pulso de MP (0,5 g) |
Melhoria |
ANA 1:320 Anti Jo-1 |
Ishikawa 20111515 Ishikawa Y, Yukawa N, Kawabata D, Ohmura K, Fujii T, Usui T, et al. A case of antisynthetase syndrome in a RA patient with anti-PL-12 antibody following treatment with etanercept. Clin Rheumatol. 2011;30:429-32.
63/f |
AR 6 m |
Buc, Tac |
Etanercept 2 m |
PM |
(+) |
PSL 1 mg/kg |
Melhoria |
ANA 1:160 Anti-PL-12 |
Riolo, 20121616 Riolo G, Towheed TE. Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis. J Rheumatol. 2012;39:192-4.
36/m |
Crohn 1 a |
Mtx |
Adalimumabe 2 s Infliximabe 1 m |
DM |
(-) |
MP, Mtx |
Melhoria |
ANA 1:640 Anti-U1 RNP |
Liu 20131717 Liu SW, Velez NF, Lam C, Femia A, Granter SR, Townsend HB, et al. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis. JAMA Dermatol. 2013;149:1204-8.
46/m |
AIJ 36 a |
Mtx |
Etanercept 10 a Adalimumabe 2 s |
DM |
(-) |
MP, Mtx |
Melhoria |
Não |